ReviewF1000Research2018
Recent advances in managing differentiated thyroid cancer.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- [A nomogram combining ultrasound radiomics and clinical features for predicting pathological invasiveness of papillary thyroid carcinoma].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Enhancement of Paclitaxel's Anticancer Efficacy in Thyroid Cancer by Isodeoxyelephantopin Through Modulation of Oxidative Stress.Food science & nutrition · 2025Article
- Tangeretin induces apoptosis and cell cycle arrest in thyroid cancer cells.Toxicological research · 2025Article
- Prognostic Indicators and Comparative Treatment Outcomes in High-Risk Thyroid Cancer with Laryngotracheal Invasion.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancers.European thyroid journal · 2024Article
- The role of miR-139-5p in radioiodine-resistant thyroid cancer.Journal of endocrinological investigation · 2023Article
- Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines · 2023Review
- Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid Cancer.Current oncology (Toronto, Ont.) · 2023Article
- Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.Molecular and clinical oncology · 2022Article
- The association of uric acid with the development of thyroid nodules: a retrospective cohort study.BMC endocrine disorders · 2022Review
- Strategies for Radioiodine Treatment: What's New.Cancers · 2022Review
- Cause of Death Among Patients With Thyroid Cancer: A Population-Based Study.Frontiers in oncology · 2022Article
- Diagnostic value of multiple diagnostic methods for lymph node metastases of papillary thyroid carcinoma: A systematic review and meta-analysis.Frontiers in oncology · 2022Review
- Bioinformatic Analysis of the Effect of theBioMed research international · 2022Article
- Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension?Journal of clinical medicine · 2021Article
- A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study).BMC endocrine disorders · 2021Article
- The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.Cells · 2021Review
- Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults.Cancers · 2020Article
- Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue.Endocrine · 2020Article
- Updates on the Management of Thyroid Cancer.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognostic tools, and treatment approaches. There has been a notable shift toward more conservative management of low- and intermediate-risk patients, characterized by less extensive surgery, more selective use of radioisotopes (for both diagnostic and therapeutic purposes), and less intensive follow-up. Furthermore, the histologic classification; tumor, node, and metastasis (TNM) staging; and American Thyroid Association risk stratification systems have been refined, and this has increased the number of patients in the low- and intermediate-risk categories. There is now a need for new, prospective data to clarify how these changing practices will impact long-term outcomes of patients with thyroid cancer, and new follow-up strategies and biomarkers are still under investigation. On the other hand, patients with more advanced or high-risk disease have a broader portfolio of options in terms of treatments and therapeutic agents, including multitarget tyrosine kinase inhibitors, more selective BRAF or MEK inhibitors, combination therapies, and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.